Tesamorelin + Ipamorelin Blend Research: A Returning Researcher FAQ

If you have bought these compounds before and you are back to place a second or third wholesale order, the useful answer is this: treat the blend question as a sourcing and verification question, not a formulation one. Real Peptides lists Tesamorelin and Ipamorelin as individual research-use-only compounds, each with its own batch documentation, and sourcing compounds separately is what keeps a lot-specific certificate of analysis meaningful. Real Peptides does not publish dosing, ratio, or preparation guidance for any compound, because these are research materials and not products for human use. What a returning buyer should actually be re-checking at reorder is batch documentation, pricing tier mechanics, and lead time.

Why your second order is a different purchase than your first

The first order evaluates a supplier. Everything after that evaluates a batch.

That distinction matters more than most buyers expect, and it is the single thing experienced purchasers do differently. Analytical purity is a property of a specific synthesis and fill run — a lot — not a property of a brand name on an invoice. A supplier can be entirely legitimate and still ship you material from a lot you have never reviewed documentation for, simply because the lot you reviewed in the spring sold through and a new one replaced it.

Peptides are produced in discrete runs. Each run is synthesized, purified, lyophilized, filled, and then assayed. Small variations in any of those steps show up in the analytical result: residual synthesis byproducts, truncated sequences, water content, or fill weight variance. Reputable suppliers handle this by testing each lot and attaching the result to that lot. The buyer's job is to close the loop — confirm that the document you are reading corresponds to the lot number printed on the vials in the box you received, not to a representative sample from a run that shipped two quarters ago.

For a returning account, that turns into a short, repeatable procedure: check the lot, pull the matching COA, confirm the compound identity and purity figure, and file it against the purchase order. It takes a few minutes per order and it is the only reliable defense against drift between batches.

What changes when two compounds arrive pre-combined

Buyers ask about combined preparations because they look operationally simpler. Analytically, they are not simpler — they move several verification questions from easy to difficult. This is worth laying out plainly, because the trade-off is procedural rather than theoretical.

None of this makes combined research preparations inherently improper in a laboratory context — researchers construct multi-component samples constantly. It does mean that if you are buying at wholesale and your documentation discipline is the thing protecting you, per-compound sourcing gives you cleaner evidence. You can hold a document for Tesamorelin and a document for Ipamorelin, each tied to its own lot, each independently verifiable.

That is also why the question "do you sell it pre-blended?" is often the wrong opening question. The better one is: can I verify, for each compound, which lot I received and what the analysis on that lot showed?

How to read batch documentation without a chemistry background

A COA is not a trust badge. It is a data record, and a buyer can audit it in a few passes.

Start with correspondence. Does the document name the same compound and the same lot number as the vial label? A COA that names a different lot, or no lot at all, documents nothing about your shipment.

Then look at method. High-performance liquid chromatography separates the components of a sample so each can be quantified; a purity percentage derived from HPLC is a statement about the proportion of the main peak relative to everything else detected. Mass spectrometry, where reported, confirms the molecular weight is consistent with the expected sequence. A purity number with no stated method behind it is a claim, not a measurement.

Then look at scope. Purity and identity are the beginning, not the end. Ask which contamination and quality panels are run on each lot and whether the results travel with the lot. A supplier that runs a defined battery on every batch can answer that question in one sentence.

Then look at access. This is where the industry splits most sharply. Some suppliers publish lab results openly so a buyer can check them without asking. Others treat documentation as a gated asset — available on request, available for a fee, available only to accounts above a certain size, or summarized in marketing copy as "third-party tested" with nothing behind the phrase. Those practices are not illegal, but they shift the burden onto you and they make year-over-year comparison across lots effectively impossible. A returning buyer who cannot compare this quarter's lot against last quarter's lot has lost the main advantage of being a returning buyer.

Concentration is the ceiling — and dosing is not on the menu

Returning buyers sometimes ask for ratio recommendations, reconstitution steps, or preparation guidance. Real Peptides does not provide any of that, in any form, for any compound in the catalog. These are research-use-only materials, they are not FDA-approved drugs, and they are not supplied for human consumption. Preparation and handling decisions belong to the receiving laboratory and its own documented procedures.

What is legitimate to discuss is the concentration framework itself, because it is simply arithmetic and it is how vials are specified. A vial label states a mass of lyophilized peptide in milligrams. When that mass is brought into solution with a given volume of solvent, the resulting concentration is expressed as milligrams per milliliter — mass divided by volume. That relationship is the entire reason vial sizes are quoted the way they are, and it is why comparing suppliers on price per vial without checking the stated mass per vial is a common and expensive error.

That is the ceiling. Anything past it — amounts, volumes, schedules, sequencing, or anything that describes material being administered to a person — is outside what a research-compound supplier should publish and outside what this article will cover.

Licensing, compliance, and the questions to take to counsel

This section is informational and is not legal advice.

The regulatory posture around research-use-only materials is genuinely unsettled in places, varies by the nature of the receiving business, and is not something any supplier should resolve on your behalf. What a serious buyer can do is arrive at their attorney's office with the right questions rather than the right assumptions.

Useful questions to put to your own counsel and, where applicable, your state board include: How does my business entity's licensure interact with purchasing and holding research-use-only materials? What recordkeeping obligations attach to materials I stock? What constraints apply to how I describe these materials in my own marketing and labeling? If I resell, what changes about my obligations compared with purchasing for internal research use? How should my supplier agreements allocate responsibility for documentation and recall handling?

Notice that each of those is a question, not a conclusion. Any supplier — including any competitor — that tells you a given category is "unregulated," "permitted in most states," or "not restricted at the federal level" is making a legal assertion it is not positioned to make and you are not positioned to rely on. Treat confident regulatory reassurance from a sales channel as a signal to slow down, not speed up.

Wholesale mechanics worth re-confirming at every reorder

Program terms are not static, and a returning account should re-confirm them rather than assume continuity.

Pricing structure. Volume-based tiers are standard across the industry, but the way they are published is not. Transparent programs show you where the tier breaks sit and what qualifies you for the next one, so you can plan an order rather than negotiate one. Opaque programs quote per conversation, which makes forecasting and margin planning guesswork. Margins and achievable markups vary widely by category, volume, and how a business positions itself — any supplier quoting you a specific margin figure is describing a hypothetical, not a commitment.

Minimums. Confirm whether minimums apply per order, per SKU, or across a mixed cart, since that determines whether you can diversify your catalog without inflating a single order.

Lead time. Confirm current fulfillment timing before you build a reorder cadence around it, and track your order rather than a calendar estimate.

Documentation continuity. Confirm that COAs for newly received lots will be available to you the same way they were on your first order. Continuity of access is the thing that makes a long-term supplier relationship auditable.

What Real Peptides does differently

Real Peptides builds the Wholesale Partner Program around verification a buyer can perform independently rather than claims a buyer has to accept.

Compounds are produced to 99%+ HPLC purity. Every batch goes through 7-panel batch testing, and the certificates of analysis are publicly verifiable — meaning a prospective or returning partner can look up lab results directly instead of requesting them, paying for them, or taking a summary on faith. That changes the economics of due diligence for a repeat buyer: comparing one lot against the next becomes a two-minute task instead of a support ticket.

Fulfillment is US-based, with orders shipping in 5–7 days. Wholesale access runs through a 3-step application, which exists so that pricing tiers and account terms are matched to a real business profile rather than quoted ad hoc.

All compounds are supplied for research use only. They are not FDA-approved drugs, they are not sold for human consumption, and no preparation or dosing guidance accompanies them.

If you are a med spa, clinic, telehealth operator, or reseller sourcing at volume and you want documentation you can check yourself before the box arrives, the Wholesale Partner Program application is the next step — three steps, business details, and tier terms matched to your ordering profile.

Returning buyers comparing lots across a catalog can review the individual listings for Tesamorelin 10mg and Ipamorelin 10mg, look at related research compounds such as CJC-1295 No DAC 10mg, or browse adjacent categories including growth factor and tissue signaling research, performance and recovery research, and the broader popular peptides collection.